Deutsche Bank sees ViroPharma's base case valuation as $38 per share, but says in an M&A scenario the company's full value could be as high as $52 per share if the potential buyer has a Hereditary Angioedema sales force. Deutsche notes that Shire (SHPG), which has been mentioned as a potential bidder for ViroPharma in media reports, sells a drug for acute HAE.
- Health Care Industry
- Investment & Company Information
- Deutsche Bank